Oncology specialist Sorrento Therapeutics (Nasdaq: SRNE) has entered into a binding agreement with medical technology company NantWorks founder, Patrick Soon-Shiong.
NantWorks and Sorrento will establish a global strategic collaboration to jointly develop immunotherapies for the treatment of cancer and auto-immune diseases. NantWorks, through a subsidiary, and Sorrento, intend to establish the first joint venture – "The Immunotherapy Antibody JV" – as an independent biotechnology company with $20 million initial joint funding.
Dr Soon-Shiong’s affiliated entity will acquire a 19.9% equity stake in Sorrento through the purchase of common stock at $5.80 per share, which was Sorrento’s closing share price on December 12. Sorrento also granted Dr Soon-Shiong a three-year warrant to purchase 1,724,138 shares of common stock at an exercise price of $5.80 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze